Further research is necessary to determine whether alterations in the patterns of serum VEGF and sVEGFR protein levels caused by combinatorial therapy with bevacizumab and FOLFIRI will affect the effectiveness of drug treatment and tumor recurrence after surgery. The gene discussed is VEGFA; the disease is neoplasm.